NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Wanbury FY26 PAT Surges 117% to ₹66.1 Cr; EPS More Than Doubles to ₹20.55
Wanbury Limited reported a robust full-year performance for FY26, with PAT growing 116.6% YoY to ₹66.1 crore and EBITDA margins expanding 330 bps to 16.5%. While Q4 FY26 revenue saw a slight 4.3% YoY decline to ₹164.6 crore due to export disruptions from the West Asia crisis, the company still achieved a 7.2% YoY growth in quarterly PAT. Operational highlights include the launch of a new Anaesthetic API and receiving zero observations from the MFDS (Korea) regulatory inspection. The company's EPS significantly improved to ₹20.55 from ₹9.32 in the previous fiscal year.
முக்கிய அம்சங்கள்
FY26 PAT grew by 116.6% YoY to ₹66.1 Cr, with PAT margins expanding by 509 bps to 10.2%.Full-year EBITDA increased 34.9% YoY to ₹107.7 Cr, driven by better product mix and procurement efficiencies.Q4 FY26 gross margin expanded by 887 bps YoY to 60.4% despite geopolitical revenue headwinds in March.Successfully launched new Anaesthetic API from Tanuku facility with commercial dispatches to Europe starting Feb 2026.Maintained a strong regulatory track record with zero observations in MFDS (Korea), USFDA, and ANVISA (Brazil) inspections.
👀 கவனிக்க வேண்டியவை
Investors should note the significant bottom-line growth and margin expansion, which suggest improved operational efficiency. The temporary Q4 revenue dip appears linked to external geopolitical factors rather than fundamental weakness, making the strong full-year EPS growth the primary focus.
Wanbury FY26 Net Profit Surges 116% to ₹66.13 Crore; Revenue Up 8.5%
Wanbury Limited reported a robust financial performance for the fiscal year ended March 31, 2026, with net profit more than doubling to ₹66.13 crore from ₹30.53 crore in FY25. Annual revenue grew 8.5% to ₹650.27 crore, driven by steady operations. A key highlight is the 18.9% reduction in finance costs to ₹29.98 crore, suggesting improved financial health and debt management. Q4FY26 profit also showed strength at ₹21.70 crore, despite a marginal year-on-year decline in quarterly revenue.
முக்கிய அம்சங்கள்
Full-year FY26 Net Profit jumped 116.6% to ₹66.13 crore compared to ₹30.53 crore in FY25.Annual Revenue from Operations grew to ₹650.27 crore in FY26 from ₹599.51 crore in the previous year.Finance costs significantly reduced to ₹29.98 crore in FY26 from ₹36.95 crore in FY25, aiding bottom-line growth.Q4FY26 Net Profit stood at ₹21.70 crore, up from ₹20.26 crore in Q4FY25.The company reported an exceptional item loss of ₹3.60 crore during the quarter and year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
The sharp increase in profitability and reduction in interest burden are strong positives for the company's valuation; investors should monitor if the company can sustain these improved margins and accelerate revenue growth.
Wanbury's Patalganga Site Receives Zero Observations from Korea FDA (MFDS)
Wanbury Limited has successfully completed a regulatory inspection by the South Korean Ministry of Food and Drug Safety (MFDS) at its Patalganga facility. The three-day inspection, conducted between April 7 and April 9, 2026, concluded with zero observations, confirming full cGMP compliance. This adds to the company's track record of clean inspections, following zero observations from the USFDA for Patalganga and Anvisa for its Tanuku plant. Furthermore, the company is expanding its API manufacturing capacity with a new block in Andhra Pradesh currently under validation.
முக்கிய அம்சங்கள்
Patalganga facility cleared the MFDS (Korea FDA) inspection with zero observations.The 3-day regulatory audit was conducted from April 7 to April 9, 2026.Both Patalganga and Tanuku sites maintain USFDA compliance with a history of zero observations.A new state-of-the-art manufacturing block for APIs is being commercialized at the Andhra Pradesh site.
👀 கவனிக்க வேண்டியவை
The successful audit strengthens Wanbury's position in regulated international markets and reflects high manufacturing standards. Investors should monitor the commercialization of the new API block in Andhra Pradesh as a potential catalyst for revenue growth.
Wanbury Limited's Secretarial Compliance Report for FY 2025-26 indicates the resolution of several significant past governance lapses. The company has successfully dematerialized 100% of promoter holdings and restored the required board and committee compositions, which previously led to fines exceeding ₹51 lakh. While a minor delay in filing the September 2025 shareholding pattern resulted in a ₹42,480 fine, the company is now largely in compliance with SEBI regulations. This transition suggests an improvement in administrative discipline compared to previous years.
முக்கிய அம்சங்கள்
Paid a fine of ₹42,480 for delayed submission of the shareholding pattern for the quarter ended September 30, 2025.Achieved 100% dematerialization of promoter shareholding, resolving a previous deficiency where only 76.74% was in demat form.Restored Board of Directors to the required minimum of 6 members and Audit/NRC committees to 3 members by January 2025.Settled substantial historical fines including ₹37.99 lakh for board composition and ₹10.57 lakh for NRC composition lapses.Confirmed compliance with Secretarial Standards (SS) and all other major SEBI regulations for the review period.
👀 கவனிக்க வேண்டியவை
Investors should view the resolution of past governance issues as a positive step, but remain cautious due to the company's history of administrative delays and fines. Monitor future filings to ensure the company maintains its restored board and committee structures consistently.
Wanbury Launches New Pediatric Products to Target ₹861 Cr Cold Preparation Market
Wanbury Limited has launched Coriminic CPM Drops and Coriminic NS Nasal Drops to align with recent DCGI regulations restricting fixed-dose cold combinations for children under 4 years. This strategic move allows the company to protect and grow its presence in the ₹861 crore Cold Preparation Liquid market. By introducing standalone formulations that avoid restricted combinations, Wanbury is positioning itself as a first-mover in safer pediatric care. The launch is expected to consolidate the company's market share in the fast-growing pediatric therapeutic segment.
முக்கிய அம்சங்கள்
Launched Coriminic CPM Drops and Coriminic NS Nasal Drops specifically for pediatric use.Strategic response to DCGI restrictions on Chlorpheniramine + Phenylephrine combinations for children under 4.Targets a significant share of the ₹861 crore Cold Preparation Liquid market in India.First-of-its-kind India-focused initiative to reposition Chlorpheniramine in a safer, regulation-aligned format.Strengthens the established Coriminic brand portfolio through localized and non-systemic relief options.
👀 கவனிக்க வேண்டியவை
Investors should view this as a proactive move to safeguard revenue from regulatory risks in the pediatric segment. Monitor the company's ability to gain prescription share from physicians transitioning away from restricted fixed-dose combinations.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Wanbury Gets Brazil ANVISA Approval for Sertraline Form II and Rs 15 Cr Metformin Order
Wanbury Limited has received ANVISA approval from Brazil for Sertraline Form II, which complements its existing Form I approval. The company currently holds a dominant 75% market share for Sertraline in Brazil, and this new approval is expected to further consolidate its position. Additionally, the company secured approval from a major customer for a special Metformin DC grade, representing a potential revenue opportunity of Rs 15 crore per annum. Both manufacturing sites in Patalganga and Tanuku remain cGMP compliant, ensuring steady production capabilities.
முக்கிய அம்சங்கள்
Received ANVISA (Brazil) approval for Sertraline Form II to strengthen market dominance.Currently holds a 75% market share for Sertraline in the Brazilian market.Secured a new Metformin DC grade approval with an estimated Rs 15 crore annual business potential.Manufacturing facilities at Patalganga and Tanuku confirmed as cGMP compliant.Approval for Form II is expected to further consolidate the company's share of business in Brazil.
👀 கவனிக்க வேண்டியவை
Investors should note the company's strong market position in Brazil and the incremental revenue from the new Metformin order. The stock remains a positive watch for growth in the API segment and continued regulatory compliance.
Wanbury Responds to Exchange Query on Missing Q2 FY26 Consolidated Financial Results
Wanbury Limited has submitted a formal response to the Stock Exchange regarding the non-submission of consolidated financial results for the quarter ended September 30, 2025. The Exchange had flagged this as a potential non-compliance with Regulation 33 of SEBI (LODR) Regulations, 2015. This clarification is significant as consolidated results are essential for understanding the performance of the company's subsidiaries alongside its standalone operations. Investors are currently awaiting the full financial picture to assess the group's total debt and profitability.
முக்கிய அம்சங்கள்
Exchange sought clarification for the quarter ended September 30, 2025, regarding missing consolidated data.The inquiry specifically pertains to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The company filed its official response to the Exchange on December 18, 2025.The discrepancy involves the non-submission of Consolidated Financial Results while standalone results were likely filed.
👀 கவனிக்க வேண்டியவை
Investors should monitor the subsequent filing of consolidated results to check for any hidden liabilities or losses in subsidiaries. Any further delay in regulatory compliance could lead to penalties or impact the stock's liquidity.
Wanbury Reports Financial Turnaround: Debt Reduced by 75% and FY25 EBITDA Reaches ₹80 Cr
Wanbury Limited has successfully executed a major financial turnaround, reducing its peak debt of ₹700 crore by approximately 75% and lowering borrowing costs from 22.5% to 12.5%. The company achieved its highest-ever operational EBITDA of ₹80 crore in FY25, driven by a dominant 30% global market share in Sertraline and 11% in Metformin. The formulations business reached financial break-even in 9MFY26, with a scale-up strategy planned for FY27. Future growth is anchored by a pipeline of four new molecule commercializations annually starting in FY27, supported by a ₹127 crore CAPEX plan for FY26-27.
முக்கிய அம்சங்கள்
Debt reduced by ~75% from peak levels with interest rates slashed from 22.5% to 12.5% effective March 2025.Global market leadership established with a 30% share in Sertraline and 11% share in Metformin APIs.Formulations segment achieved financial break-even in 9MFY26 after years of turnaround efforts.Aggressive CAPEX plan of ₹64 Cr for FY26 and ₹63 Cr for FY27 focusing on new product blocks and clean rooms.Operational EBITDA scaled approximately 3X between FY23 and FY25, reaching a record ₹80 crore.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's transition from a debt-heavy turnaround story to a growth-oriented API player with a de-risked balance sheet. Monitor the successful launch of the new anaesthetic molecule in Q4FY26 as a litmus test for the upcoming high-frequency product launch strategy.
Wanbury Limited has officially released its un-audited financial results for the third quarter and nine-month period ending December 31, 2025 (FY26). The announcement was communicated via a formal press release dated February 6, 2026. This filing is a standard regulatory requirement providing transparency into the company's recent operational performance. Investors should now examine the detailed profit and loss statements to evaluate the company's growth trajectory in the pharmaceutical sector.
முக்கிய அம்சங்கள்
Release of un-audited financial results for the quarter ended December 31, 2025.Consolidated and standalone performance for the 9-month (9M) period of FY26 included.Official press release issued on February 6, 2026, to provide management context.Compliance with SEBI Listing Obligations and Disclosure Requirements confirmed.
👀 கவனிக்க வேண்டியவை
Investors should review the full financial tables for specific trends in revenue and EBITDA margins. Compare the Q3 performance against previous quarters to assess if the company is maintaining its growth momentum.
Wanbury Limited's board met on February 5, 2026, to approve the un-audited financial results for the quarter ended December 31, 2025. The company announced the grant of 60,000 new stock options to employees at an exercise price of ₹130 per share. Additionally, the board approved the allotment of 47,400 equity shares following the exercise of previously vested options, generating ₹4.74 lakh in capital. As a result, the company's total paid-up share capital has increased to ₹34.94 crore.
முக்கிய அம்சங்கள்
Approved un-audited financial results for the third quarter and nine months ended December 31, 2025Granted 60,000 new stock options under ESOP 2016 at a pricing formula of 50% of the closing market price (₹130 per share)Allotted 47,400 equity shares of face value ₹10 each to employees upon exercise of vested optionsTotal paid-up share capital increased from ₹34,89,19,980 to ₹34,93,93,980Realized ₹4,74,000 in cash from the exercise of 47,400 options
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed Q3 financial results separately to evaluate the company's fundamental performance. The current equity dilution from ESOPs is minimal and part of standard employee retention strategies.
Wanbury Achieves First Sales and Commercial Shipment of New Anaesthetic API
Wanbury Limited has successfully commenced commercial shipments of its new high-demand Anaesthetic API from its Tanuku facility in Andhra Pradesh. The first sale and invoicing milestone was achieved on January 30, 2026, for a leading European customer. This move marks the company's entry into a high-growth segment just months after the initial product launch. Management expects this to signal rapid growth and production ramp-up, strengthening its global API portfolio which already serves over 50 countries.
முக்கிய அம்சங்கள்
Achieved first sales and invoicing of a new high-demand Anaesthetic API on January 30, 2026Commenced commercial shipments to a leading European customer from the USFDA/EUGMP approved Tanuku facilityCommercialization achieved within just months of the product launch, indicating high operational efficiencyManagement signals rapid growth ahead with plans to multiply production capacity and scaling fast
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution from this new API in upcoming quarterly results to validate the scale of the production ramp-up. The successful entry into the specialized anaesthetic segment enhances the company's margin profile and global competitiveness.
Wanbury Launches Anaesthetic API Production; Targets ₹100 Cr+ Incremental Revenue in FY27
Wanbury Limited has commenced commercial production of a high-potent anaesthetic API at its Tanuku facility in Andhra Pradesh. This move is expected to generate incremental revenues of approximately ₹18 crore in Q4 FY26 and over ₹100 crore in FY 2026-27. The company is also expanding its capacity with a multi-purpose intermediate block scheduled for completion by March 2026. This expansion aims to capture a share of the global market for these new APIs, which is currently valued at over ₹5,000 crore.
முக்கிய அம்சங்கள்
Commenced commercial production of a key anaesthetic API at the state-of-the-art Tanuku facility.Projected incremental revenue of over ₹100 crore in FY 2026-27 from the new API production.Expected immediate revenue contribution of approximately ₹18 crore in Q4 FY 2025-26.On track to launch four additional high-value APIs (Antidiabetic, Anticoagulant, etc.) by March 2026.Targets a global market opportunity for these molecules valued at over ₹5,000 crore.
👀 கவனிக்க வேண்டியவை
Investors should track the company's ability to scale production and meet the ₹18 crore revenue target in Q4 FY26 as a sign of execution capability. The successful launch of the additional four APIs in March 2026 could be a further re-rating trigger for the stock.
Wanbury Limited EGM on January 05, 2026 for Director Re-Appointment
Wanbury Limited is holding an Extraordinary General Meeting (EGM) on January 05, 2026, via video conferencing to re-appoint Mr. Manojkumar Khubchand Gursahani as a Non-Executive Independent Director. The re-appointment is for a term of one year, effective from January 08, 2026, until January 07, 2027. Shareholders can participate through video conferencing, with a facility for at least 1000 members on a first-come, first-served basis. Remote e-voting will be available from January 02, 2026, at 09:00 A.M. to January 04, 2026, at 05:00 P.M.
முக்கிய அம்சங்கள்
EGM to be held on January 05, 2026, at 03:00 P.M.Re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN- 01064558) as Non-Executive Independent DirectorRe-appointment effective from January 08, 2026 upto 07th January, 2027Remote e-voting begins on January 2, 2026 at 09:00 A.M. and ends on January 4, 2026 at 05:00 P.M.Cut-off date (record date) of Monday, 29th December, 2025
👀 கவனிக்க வேண்டியவை
Shareholders should review the details of the resolution regarding the director's re-appointment and cast their votes via remote e-voting between January 2nd and 4th, 2026. Monitor the company's website for further updates and participation instructions for the EGM.
Wanbury Board Meeting Outcome: Re-appointment of Independent Director
Wanbury Limited's board has approved the re-appointment of Mr. Manojkumar Khubchand Gursahani as a Non-Executive Independent Director for a period of 1 year, effective from January 08, 2026, to January 07, 2027. This re-appointment is subject to shareholders' approval via a special resolution in an upcoming extra-ordinary general meeting to be held on January 05, 2026. Mr. Gursahani has confirmed that he continues to meet the criteria of 'Independence' under the Companies Act, 2013 and SEBI Listing Regulations. The board meeting commenced at 04:30 P.M. and concluded at 05:15 P.M.
முக்கிய அம்சங்கள்
Re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN: 01064558) as Non-Executive Independent Director.Tenure is for 1 (One) year effective from January 08, 2026 to January 07, 2027.Extra Ordinary General Meeting (EGM) to be held on Monday, January 05, 2026 for shareholders' approval.Board meeting commenced at 04:30 P.M. and concluded at 05:15 P.M.
👀 கவனிக்க வேண்டியவை
Shareholders should review the details of Mr. Gursahani's profile and consider voting on the resolution for his re-appointment at the EGM on January 05, 2026. Monitor company announcements for further updates.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
